Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) Income towards Parent Company (2024 - 2025)

Historic Income towards Parent Company for Pyxis Oncology (PYXS) over the last 2 years, with Q3 2025 value amounting to -$22.0 million.

  • Pyxis Oncology's Income towards Parent Company fell 377.31% to -$22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$97.6 million, marking a year-over-year change of. This contributed to the annual value of -$77.3 million for FY2024, which is 465.69% down from last year.
  • Pyxis Oncology's Income towards Parent Company amounted to -$22.0 million in Q3 2025, which was down 377.31% from -$18.4 million recorded in Q2 2025.
  • Pyxis Oncology's 5-year Income towards Parent Company high stood at -$4.0 million for Q1 2024, and its period low was -$35.6 million during Q4 2024.